Navigation Links
BioWa Announces License of Biowa's Potelligent(R) Technology to KaloBios Pharmaceuticals
Date:10/28/2008

PRINCETON, N.J., Oct. 28 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into an agreement with KaloBios Pharmaceuticals, Inc., under which BioWa licenses to KaloBios its POTELLIGENT(R) Technology for enhancing the antibody-dependent cellular cytotoxicity (ADDC) of select KaloBios therapeutic antibodies.

"We are excited about this strategic partnership with KaloBios," commented Dr. Masamichi Koike, President and CEO of BioWa. "With KaloBios' specialized expertise in the antibody field, this collaboration will further reinforce our effort to bring the benefit of the technology to patients in need as quickly as possible."

Under the terms of the license agreement, BioWa grants KaloBios non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT(R) Technology for an undisclosed number of targets. In return, BioWa will receive upfront payment, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform co
'/>"/>

SOURCE BioWa, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
3. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
4. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Libreville International Conference 2-3 June 2010 2
...France, April 23 , - Strong 10.3% Growth in F...the world leader in ophthalmic optics, today,annou...the three months ended,March 31, 2009, representin...f 2008. Excluding the currency effect, growth was ...and early in the year, revenue was down just 1%,li...
...l 22 Hovione held today the opening,ceremony of i...ing site in,Cork. Hovione contracted with Pfizer l...anufacturing Lipitor(R) since 1997. The handover o...ction closed on the 8th; going forward,Hovione wil...e for Pfizer but,will mostly make use of the avail...
...inducted into National Academy of Sciences for gro... WASHINGTON, April 22 Sir Philip Cohen of Scotlan...he U.S. National Academy of Sciences (NAS) during ...8:00 p.m. at the NAS building for his excellence i...of only four Scottish scientists ever inducted int...
Other Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Hovione Opens its New API Plant in Cork 2Hovione Opens its New API Plant in Cork 3United States Recognizes Leading Scottish Scientist for Disease Research 2
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)PHILADELPHIA Now in its 32nd year, the CTRC-AACR San Antonio Breast Cancer Symposium continues to attract the best in breast cancer science and world leaders from industry and academia with the goal
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2Forest deal at Copenhagen must avoid creating 'carbon refugees' 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 1HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 2HBA Global Announces Finalists for the 2009 International Package Design Awards 28IPDA 29 55290 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 1CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 2CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 3CardioDx Completes Validation Study of First Of Its Kind Genomic Test for Coronary Artery Disease 4894 4Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 1Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 2Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 3Adamas Pharmaceuticals Expands Management Team 3B Names Michael D Coffee and Amy K Patick to Executive Positions 55287 4
...ester scientists are to investigate the biological... after Alzheimer,s, thanks to a prestigious 1.9 mi...earch Council. , Frontotemporal lobar degeneratio...rontal and temporal lobes of the brain and are cha...rather than the memory loss associated with Alzhei...
...utions to Identify Individuals for Access to ...ions, WALL, N.J., Sept. 22 BIO-key International...er-based biometric,identification and wireless pub...etwork, is showcasing its fingerprint biometric so... being held at the Moscone Center in San,Francisco...
...A glitch in the ability to move iron around in cel...idosis (ML4) and the suite of symptoms---mental re...ies---that accompany it, new research at the Unive... may be involved in aging and neurodegenerative di...ead author Haoxing Xu, an assistant professor of m...
Other Biology News:£2 million study to reveal workings of dementia genes 2BIO-key(R) International To Exhibit at Oracle OpenWorld 2BIO-key(R) International To Exhibit at Oracle OpenWorld 3BIO-key(R) International To Exhibit at Oracle OpenWorld 4Iron-moving malfunction may underlie neurodegenerative diseases, aging 2Iron-moving malfunction may underlie neurodegenerative diseases, aging 3
... containing a clone of the human Topoisomerase II ... topological state of nucleic acids by passing an ...enerates a separate DNA helix (1,2) . As a result ...enzyme can relax negatively or positively supercoi...
...I catalyzes the template-directed polymerization o...DNA Polymerase I possesses a 3?5 exonuclease activ...rror rate during DNA replication, and also contain...zyme to replace nucleotides in the growing strand ...
...e Klenow Fragment is a genetically engineered Klen...vity has been removed, leaving only the 5 to 3 pol...ctivity makes Exo- Klenow Fragment the enzyme of c...s by the random primed method, and for DNA sequenc...
T7 RNA Polymerase from Invitrogen
Biology Products: